Abstract:Objective To establish an Alzheimer's disease (AD) mouse model, investigate the behavioral performance changes and intracerebral molecular changes induced by bilateral intracerebroventricular injection of streptozotocin (STZ/I.C.V), and explore the potential pathogenesis of AD. Methods An AD mouse model was established by STZ/I.C.V. The behavioral performance was observed via the open field test (OFT), novel object recognition test (NOR), and tail suspension test (TST). The mRNA and protein expressions of interleukin 1β (IL-1β), interleukin 6 (IL-6), and tumor necrosis factor α (TNF-α) in the hippocampus were measured via qPCR and Western blot. The expression of β-amyloid 1–42 (Aβ 1–42 ), phosphorylated Tau protein (p-Tau (Ser396)), Tau5, β-site amyloid precursor protein (APP) cleaving enzyme (BACE), insulin receptor substrate 1 (IRS1), brain-derived neurotrophic factor (BDNF), Copine6, synaptotagmin-1 (Syt-1), synapsin-1, phosphoinositol 3 kinase (PI3K), serine/threonine kinase (Akt), phosphorylated serine/threonine kinase (p-Akt (Ser473)), triggering receptor expressed on myeloid cells-1/2 (TREM1/2) were detected using Western blot, and the expression of glial fibrillary acidic protein (GFAP), ionized calcium binding adapter molecule 1 (IBA1), Aβ 1–42 , p-Tau(Ser396), Syt-1, BDNF were measured via immunofluorescence staining. Results STZ/I.C.V induced AD-like neuropsychiatric behaviors in mice, as indicated by the impairment of learning and memory, together with the reduced spontaneous movement and exploratory behavior. The expression of BACE, Aβ 1–42 , p-Tau(Ser396), and TREM2 were significantly increased in the hippocampus of model mice, while the expression of IRS1, BDNF, Copine6, Syt-1, synapsin-1, PI3K, p-Akt(Ser473), and TREM1 were decreased as compared with that of the controls. Furthermore, the model mice presented a hyperactivation of astrocytes and microglia in the hippocampus, accompanied by the increased mRNA and protein expressions of IL-1β, IL-6 and TNF-α. Conclusion STZ/I.C.V is an effective way to induce AD mice model, with not only AD-like neuropsychiatric behaviors, but also typic AD-like neuropathological features including neurofibrillary tangles, deposit of β-amyloid (Aβ), neuroinflammation, and imbalanced synaptic plasticity.

Effect of intraperitoneal or intracerebroventricular injection of streptozotocin on learning and memory in mice

Impaired Learning and Memory Ability Induced by a Bilaterally Hippocampal Injection of Streptozotocin in Mice: Involved With the Adaptive Changes of Synaptic Plasticity

The effect of intracerebroventricular injection of streptozotocin on rat spatial learning/memory,the number of hippocampal CA1 neurons and the expression of hippocampal synaptophysin

Expression Changes of Growth-Associated Protein-43 (Gap-43) and Mitogen-Activated Protein Kinase Phosphatase-1 (Mkp-1) and in Hippocampus of Streptozotocin-Induced Diabetic Cognitive Impairment Rats

Bilateral intracerebroventricular injection of streptozotocin induces AD-like behavioral impairments and neuropathological features in mice: Involved with the fundamental role of neuroinflammation

Effect and Mechanism of Auricularia Auriculajudae Polysaccharide in Hippocampus of Streptozotocin‐induced Diabetic Cognitive Impairment Rats

Intranasal Insulin Ameliorates Cerebral Hypometabolism, Neuronal Loss, and Astrogliosis in Streptozotocin-Induced Alzheimer’s Rat Model

AD-Like Neuropsychiatric Dysfunction in a Mice Model Induced by a Combination of High-Fat Diet and Intraperitoneal Injection of Streptozotocin

Enhancement of Β-Amyloid Oligomer Accumulation after Intracerebroventricular Injection of Streptozotocin, Which Involves Central Insulin Signaling in a Transgenic Mouse Model

Change of hippocampal synaptophysin in rats after intracerebroventricular streptozotocin treated rates

Brain aging and AD-like pathology in streptozotocin-induced diabetic rats.

Intracerebroventricular Injection of Streptozotocin Caused Brain Energy Deficiency and Spatial Memory Impairment in Rats

A New Approach to Model Sporadic Alzheimer’s Disease by Intracerebroventricular Streptozotocin Injection in APP/PS1 Mice

Long-term treatment with intranasal insulin ameliorates cognitive impairment, tau hyperphosphorylation, and microglial activation in a streptozotocin-induced Alzheimer’s rat model

Investigating the Impact of Intracerebroventricular Streptozotocin on Female Rats with and without Ovaries: Implications for Alzheimer's Disease

Cognitive dysfunction and N-Methyl-D-Aspartate receptor expression in streptozotocin-diabetic rats

Effect of Pioglitazone on the spatial memory and hippocampal structure in model of SAD rates

Intracerebroventricular streptozotocin administration impairs mitochondrial calcium homeostasis and bioenergetics in memory-sensitive rat brain regions

1145 RTMS TREATMENT IMPROVED COGNITIVE DYSFUNCTION THROUGH ADULT NEUROGENESIS IN ICV-STZ RAT MODEL OF SPORADIC ALZHEIMER'S DISEASE

Intracerebroventricular Injection of Streptozotocin Caused Similar Changes of Rat Brain to Sporadic Alzheimer's Disease with Energy Deficiency and Increased Aβ1-40,Aβ1-42 Positive Cells

Age-dependent impact of streptozotocin on metabolic endpoints and Alzheimer's disease pathologies in 3xTg-AD mice